@article{f8de5c52d39e4f33b7fb3fe147613838,
title = "BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner",
abstract = "Purpose of Review: This review focuses on the feasibility of combining Bruton{\textquoteright}s tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with these agents are presented. Recent Findings: BTKis and CAR T-cell therapy have revolutionized the treatment paradigm for R/R MCL. Ibrutinib, acalabrutinib, and zanubrutinib are covalent irreversible BTKis approved for R/R MCL. Brexucabtagene autoleucel was the first CAR T-cell therapy approved for R/R MCL based on findings from the ZUMA-2 trial. There is evidence to suggest that combination treatment with BTKis and CAR T-cell therapy may improve CAR T-cell efficacy. Summary: As BTKis and CAR T-cell therapy become mainstays in R/R MCL therapy, combination treatment strategies should be evaluated for their potential benefit in R/R MCL.",
keywords = "Bruton{\textquoteright}s tyrosine kinase, Chimeric antigen receptor T-cell therapy, Combination therapy, Relapsed/refractory mantle cell lymphoma",
author = "Munoz, {Javier L.} and Yucai Wang and Preetesh Jain and Michael Wang",
note = "Funding Information: P. Jain reports other support from Eli Lilly. Y. Wang reports other support from Incyte, InnoCare, Loxo Oncology, Novartis, Genentech, Eli Lilly, Kite, and TG therapeutics, all outside the submitted work. M. Wang reports grants from Molecular Templates, personal fees from Anticancer Association, Bayer Healthcare, CStone, Chinese Medical Association, Clinical Care Options, DTRM Biopharma (Cayman) Limited, Dava Oncology, Epizyme, Genentech, Hebei Cancer Prevention Federation, CAHON, Imbruvica, Imedex, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals. OMI, Physicians Education Resources (PER), Scripps, The First Affiliated Hospital of Zhejiang University; grants and personal fees from Acerta Pharma, BeiGene, AstraZeneca, Pharmacyclics, BioInvent, Celgene, Innocare, Janssen, Juno, Kite Pharma, Loxo Oncology, and Oncternal, VelosBio, all outside the submitted work. J.L. Munoz reports consulting fees from Pharmacyclics/AbbVie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, Bristol Myers Squibb, Kyowa, Alexion, Fosun Kite, Innovent Bio, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, BeiGene, Servier Laboratories, Novartis, MorphoSys/Incyte, and Eli Lilly; research funding from Bayer, Gilead/Kite Pharma, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, and Millennium; honoraria from Targeted Oncology, OncView, Curio, Kyowa, Physicians{\textquoteright} Education Resource, and Seattle Genetics; and participation in speaker bureaus sponsored by Gilead/Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, BeiGene, Verastem Oncology, AstraZeneca, Celgene/Bristol Myers Squibb, and Genentech/Roche, all outside the submitted work. Funding Information: Medical writing/editorial support was provided by Kalpana Vijayan, PhD, Cheryl Casterline, MA, and Elizabeth Hermans, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and was funded by BeiGene, Inc. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = oct,
doi = "10.1007/s11912-022-01286-0",
language = "English (US)",
volume = "24",
pages = "1299--1311",
journal = "Current oncology reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "10",
}